Prothena Corporation plc has released a corporate presentation outlining its ongoing efforts to develop therapies targeting diseases related to protein dysregulation, including Parkinson's disease, Alzheimer's disease, and transthyretin amyloidosis $(ATTR)$. The presentation highlights the company's active development pipeline, featuring key programs such as PRX019 for neurodegenerative diseases (with Phase 1 trial completion expected in 2026), BMS-986446 for Alzheimer's disease (Phase 2 trial completion expected in 2027), prasinezumab for Parkinson's disease (currently in Phase 3), and coramitug for ATTR cardiomyopathy (Phase 3 trial completion anticipated). Prothena also details its collaborations and potential milestone payments related to these programs, including clinical milestones of up to $105 million by the end of 2026 and additional regulatory and sales milestones. The presentation notes ongoing open-label extension studies for prasinezumab, which have provided biomarker evidence of impact on disease biology and support for the slowing of disease progression in Parkinson's disease. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prothena Corporation plc published the original content used to generate this news brief on January 11, 2026, and is solely responsible for the information contained therein.